Danske Bank A S Makes New Investment in Edwards Lifesciences Corporation $EW

Danske Bank A S bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, Holdings Channel reports. The firm bought 524,490 shares of the medical research company’s stock, valued at approximately $47,445,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences during the 1st quarter valued at $25,000. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth $25,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $26,000. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the first quarter worth $26,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on EW. JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Citigroup upped their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, Truist Financial raised their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Price Performance

EW opened at $92.36 on Thursday. The business has a fifty day moving average of $89.03 and a 200 day moving average of $84.57. The stock has a market cap of $53.18 billion, a P/E ratio of 53.08, a PEG ratio of 2.29 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences’s revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,570 shares of company stock valued at $2,219,390 over the last three months. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.